Paul Diehl

  • San Francisco-area biotech consultant with more than 20 years of experience
  • Ph.D. in biochemistry from Washington State University
  • Worked with numerous biotech companies


Paul Diehl, Ph.D. is a San Francisco-area biotech consultant who wrote about biotech and biomedical topics for The Balance from April 2012 to March 2014. He has over 20 years of experience in the field including assessing, introducing, and supporting new technology for life science research.

He has held various marketing and business development positions at B-Bridge International, Arcturus Bioscience, Agilent Laboratories, Display Systems Biotech, and Clontech Laboratories, as well as worked with several other companies on a contract basis.

Paul has also published a number of freelance and contracted articles reviewing laboratory products, new therapeutics, and research developments.


Paul holds a bachelor's degree in biology from La Salle University and a Ph.D. in biochemistry from Washington State University.

About The Balance and Dotdash

The Balance makes personal finance easy to understand. It is home to experts who provide clear, practical advice on managing your money. Whether you’re looking to invest, buy a home, save for retirement, or achieve another financial goal, The Balance will answer your questions with straightforward personal financial advice.

The Balance is part of the Dotdash publishing family. For more than 20 years, Dotdash brands have been helping people find answers, solve problems, and get inspired. We are one of the top-20 largest content publishers on the internet, according to comScore, and reach more than 30% of the U.S. population every month. Most recently, Dotdash was named Publisher of the year by Digiday, a leading industry publication.